View Older Stories

Jan 20, 2026 04:38AM Madrigal Pharmaceuticals (MDGL) PT Raised to $745 at Citizens: '27 Data Awaited

Jan 14, 2026 12:45AM Goldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

Jan 12, 2026 09:32AM Truist on Madrigal Pharmaceuticals (MDGL): 'In-Licensed Asset Potentially Strengthens Pipeline'

Jan 6, 2026 05:33AM Wolfe Research Downgrades Madrigal Pharmaceuticals (MDGL) to Peerperform

Dec 19, 2025 08:28AM Madrigal Pharmaceuticals (MDGL) PT Raised to $900 as Piper Sandler Recommends Buy

Dec 8, 2025 07:32AM Piper Sandler on Biotechnology: 'What Commercial Names to Own in 2026?'

Nov 21, 2025 01:28PM Madrigal Pharmaceuticals (MDGL) PT Raised to $620 at H.C. Wainwright

Nov 20, 2025 04:02AM Madrigal Pharmaceuticals (MDGL) PT Raised to $650 at Oppenheimer

Nov 19, 2025 06:05AM Madrigal Pharmaceuticals (MDGL) PT Raised to $640 at Truist Securities, 'We remain buyers'

Nov 13, 2025 05:33AM Madrigal Pharmaceuticals (MDGL) PT Raised to $579 at Wolfe Research

Nov 10, 2025 08:02AM Madrigal reports positive two-year data for Rezdiffra in MASH cirrhosis patients

Nov 5, 2025 05:23AM Madrigal Pharmaceuticals (MDGL) PT Raised to $510 at Leerink Partners

Nov 5, 2025 04:59AM Madrigal Pharmaceuticals (MDGL) PT Raised to $527 at Citizens on Redziffra Sales

Nov 4, 2025 04:08PM Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals (MDGL) to Overweight, 'clarity on 2026 growth and no major near-term headwinds for the stock'

Nov 4, 2025 07:04AM Madrigal Pharma (MDGL) Misses Q3 EPS by 311c

Nov 3, 2025 06:28AM BofA Securities Upgrades Madrigal Pharmaceuticals (MDGL) to Neutral

Oct 16, 2025 04:19AM Citizens Reiterates Market Outperform Rating on Madrigal Pharmaceuticals (MDGL) Amid Rezdiffra Momentum

Oct 15, 2025 06:19AM Madrigal Pharmaceuticals (MDGL) PT Raised to $540 at Piper Sandler

Oct 14, 2025 04:03PM Truist Securities Starts Madrigal Pharmaceuticals (MDGL) at Buy

Oct 10, 2025 05:29AM Madrigal Pharmaceuticals (MDGL) PT Raised to $590 at Oppenheimer

Sep 24, 2025 08:50AM UBS Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL) as Management Confident in MASH Market Opportunity

Sep 12, 2025 06:23AM Madrigal Pharmaceuticals (MDGL) PT Raised to $526 at Canaccord Genuity

Sep 4, 2025 06:14AM H.C. Wainwright Starts Madrigal Pharmaceuticals (MDGL) at Buy

Aug 26, 2025 08:38AM Madrigal Pharmaceuticals (MDGL) PT Raised at TD Cowen on EU approval of Rezdiffra

Aug 22, 2025 07:17AM Cantor Fitzgerald Reiterates Neutral Rating on Madrigal Pharmaceuticals (MDGL)

Aug 20, 2025 08:54AM Piper Sandler: 'We Remain Bullish on Madrigal Pharmaceuticals (MDGL)'

Aug 20, 2025 04:16AM Madrigal Pharmaceuticals (MDGL) PT Raised to $485 at Citizens JMP

Aug 19, 2025 04:05PM Madrigal gets EU approval for first MASH treatment Rezdiffra

Aug 18, 2025 10:59AM Goldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

Aug 12, 2025 10:12AM Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)

Aug 12, 2025 05:22AM Madrigal Pharmaceuticals (MDGL) PT Raised to $502 at Jefferies

Aug 5, 2025 04:25PM Goldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

Aug 5, 2025 07:06AM Madrigal Pharma (MDGL) Tops Q2 EPS by $1.73, Beats on Revenue

Jul 22, 2025 08:00AM Madrigal secures $500 million credit facility from Blue Owl

Jul 22, 2025 04:06AM Citizens JMP Reiterates Market Outperform Rating on Madrigal Pharmaceuticals (MDGL)

Jul 16, 2025 02:48PM Madrigal Pharmaceuticals (MDGL) PT Raised to $500 at Oppenheimer on Rezdiffra Patent

Jul 16, 2025 08:02AM Madrigal receives patent allowance for Rezdiffra through 2044

Jul 2, 2025 04:10AM Citizens JMP Reiterates Market Outperform Rating on Madrigal Pharmaceuticals (MDGL)

Jun 20, 2025 06:31AM Madrigal Pharma (MDGL) Receives Positive CHMP Opinion for Resmetirom for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Jun 5, 2025 04:26AM Citizens JMP Reiterates Market Outperform Rating on Madrigal Pharmaceuticals (MDGL)

May 13, 2025 04:11PM Citi Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

May 13, 2025 02:23PM BofA Securities Reiterates Underperform Rating on Madrigal Pharmaceuticals (MDGL), PT $248

May 1, 2025 07:13AM Madrigal Pharma (MDGL) Tops Q1 EPS by 54c

Apr 29, 2025 07:52AM Cantor Fitzgerald Reiterates Neutral Rating on Madrigal Pharmaceuticals (MDGL)

Apr 24, 2025 04:13AM Citizens JMP Reiterates Market Outperform Rating on Madrigal Pharmaceuticals (MDGL)

Apr 11, 2025 09:44AM Piper Sandler: 'What Biotech Names to Own in Market Volatility'

Mar 11, 2025 08:01AM Madrigal Pharma (MDGL) Appoints Jacqualyn A. Fouse to its Board

Feb 27, 2025 10:10AM UBS Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

Feb 27, 2025 06:05AM Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at H.C. Wainwright

Feb 27, 2025 04:26AM Madrigal Pharmaceuticals (MDGL) PT Raised to $443 at Citizens JMP

View Older Stories